BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ostora oral salmon calcitonin regulatory update

Tarsa pushed back its regulatory timeline for Ostora oral recombinant salmon calcitonin and now plans to submit an NDA to FDA in 2H12 for the postmenopausal osteoporosis product. Tarsa had planned to submit the application by year end. Tarsa said the new timeline partly reflects the recent announcement from...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >